The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

BofA Securities has recently reduced Hims & Hers Health Inc (HIMS) stock to Underperform rating, as announced on November 14, 2024, according to Finviz. Earlier, on August 22, 2024, Needham had ...